1 Fava M, Mallinckrodt CH, Detke MJ et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65: 521–30.
2 Perahia DG, Quail D, Desaiah D et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009; 43: 512–8.
3 Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003; 64 (Suppl. 15) : 13–7.
4 Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62: 869–77.
5 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.
6 Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50: 97–108.
7 Keller MB, Lavori PW, Mueller TI et al. Time to recovery, chronic- ity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49: 809–16.
8 Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095–105.
9 Perahia DG, Quail D, Desaiah D et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a mul- ticenter trial comparing 2 switching techniques. J Clin Psychiatry 2008; 69: 95–105.
10 Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Compara- tive affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo , human serotonin receptor subtypes, and other neuronal receptors. Neuropsychophar- macology 2001; 25: 871–80.
11 Wohlreich MM, Mallinckrodt CH, Prakash A et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007; 24: 41–52.
12 Goldstein DJ, Lu Y, Detke MJ et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 45: 17–28.
13 Brecht S, Courtecuisse C, Debieuvre C et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007; 68: 1707–16.
14 Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006; 21: 311–7.
15 Maier W, Phillip M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985; 18: 114–5.
16 Bymaster FP, Lee TC, Knadler MP et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, 
17 Mallinckrodt CH, Watkin JG, Liu C et al. Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005; 5: 1.
18 American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th edn, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press, 2000.
19 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
20 Thase ME, Pritchett YL, Ossanna MJ et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27: 672–6.
21 Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171–80.
22 Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005; 21: 170–7.
23 Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo- controlled trial. J Clin Psychiatry 2002; 63: 308–15.
24 Hartford JT, Endicott J, Kornstein SG et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry 2008; 10: 197–204.
25 Russell JM, Weisberg R, Fava M et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008; 25: E1–11.
26 Leuchter AF, Husain MM, Cook IA et al. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 2010; 40: 239–51.
27 Arnold LM, Meyers AL, Sunderajan P et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008; 20: 187–93.
28 Nemeroff CB, Schatzberg AF, Goldstein DJ et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106–32.
29 Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237–44.
30 Wohlreich MM, Martinez JM, Mallinckrodt CH et al. An open- label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005; 25: 552–60.